Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer.

Saved in:
Bibliographic Details
Title: Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer.
Authors: Westcott PMK; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Sacks NJ; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Schenkel JM; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Ely ZA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Smith O; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Hauck H; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Jaeger AM; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Zhang D; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Backlund CM; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Beytagh MC; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Patten JJ; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Elbashir R; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Eng G; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Irvine DJ; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.; Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA, USA., Yilmaz OH; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA., Jacks T; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. tjacks@mit.edu.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. tjacks@mit.edu.
Source: Nature cancer [Nat Cancer] 2021 Oct; Vol. 2 (10), pp. 1071-1085. Date of Electronic Publication: 2021 Sep 30.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer
Database: MEDLINE Ultimate
Description
ISSN:2662-1347
DOI:10.1038/s43018-021-00247-z